VEGF expression and possible response to angiogenesis inhibitor bevacizumab ASPS mets

[D.ap]

Vascular-endothelial-growth-factor (VEGF) expression and
possible response to angiogenesis inhibitor bevacizumab in
metastatic alveolar soft part sarcoma
Amedeo A Azizi,* Christine Haberler,* Thomas Czech, Astrid Gupper, Daniela Prayer, Helene Breitschopf, Till Acker, Irene Slav

The decision to use antiangiogenic treatment for our
patient was based on three factors: (1) the high
vascularisation of the tumour, (2) the ineffectiveness of
cytotoxic chemotherapy regimens in our patient, and
(3) the known benefit of antiangiogenic treatment in
tumours that are highly vascularised (eg, angioblastoma)3
and slow-growing (eg, renal-cell carcinomas).4
Antiangiogenic drugs can be classifi ed according to their
mechanism of action—eg, those inhibiting the breakdown
of basement membrane, endothelial-cell migration and
proliferation, cell-adhesion molecules, or angiogenic
growth factors or their receptors.5,6 Additional compounds
with established antineoplastic or antiproliferative
functions, such as thalidomide or inter feron alfa-2b, have
been reported to have anti angiogenic activities.7,8


http://cureasps.org/library/9_Avastin_Vienna_06.pdf

http://oncology.thelancet.com Vol 7 June 2006